A Phase II Trial Of Oral Bicalutamide With Subcutaneous Goserelin In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Carcinoma In Second Or Greater Remission
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 18 Jun 2013 Biomarkers information updated
- 17 Dec 2009 Actual end date (April 2004) added as reported by ClinicalTrials.gov record.
- 01 Dec 2007 Status changed from in progress to completed.